Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

28 oktober 2026 uppdaterad av: Boehringer Ingelheim

A Phase III, Randomised, Double-blind, Parallel-group, 56-week Study, Evaluating the Efficacy and Safety of Survodutide (BI 456906), Compared With Placebo, in Participants With Type 2 Diabetes, as an Adjunct to Diet and Physical Activity Alone or in Combination With Either Oral Antidiabetic Medications or Insulin

This study aims to find out whether a study medicine called survodutide helps people control their blood sugar. Adults who live with type 2 diabetes and with a body mass index (BMI) of 23 kg/m2 or higher can join.

The study has 3 parts. In each part the study compares survodutide with placebo. Survodutide is being developed to treat several health problems including type 2 diabetes. Placebo looks like survodutide but does not contain any medicine.

Depending on a person's diabetes treatment, a person will be assigned either to

  • Part A: healthy eating and physical activity
  • Part B: diabetes tablets (no injection of insulin)
  • Part C: injection of insulin (with or without diabetes tablets)

Participants are randomly put into 1 of 3 groups, which means the group is chosen by chance. Two groups of participants get survodutide at different dose levels, and the third group gets placebo as injection under the skin once a week. You have a 2 in 3 chance of getting survodutide. During the study, participants continue their regular diabetes treatment.

Participants are in the study for about 1 year and 2 months. During this time, they attend up to 12 visits at the site and receive at least 9 phone calls. Study doctors regularly test participants' blood sugar by checking their HbA1c values and other laboratory test results. The study doctor also regularly checks participants' health and takes note of any changes. For each study part, the results will be compared between the survodutide and the placebo group to see whether the treatment works.

Studieöversikt

Status

Rekrytering

Betingelser

Studietyp

Interventionell

Inskrivning (Beräknad)

600

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • New South Wales
      • Camperdown, New South Wales, Australien, 2050
    • Queensland
      • Meadowbrook, Queensland, Australien, 4131
    • South Australia
      • Oaklands Park, South Australia, Australien, 5046
        • Rekrytering
        • Southern Adelaide Diabetes & Endocrine services
        • Kontakt:
    • Victoria
      • Melbourne, Victoria, Australien, 3004
        • Har inte rekryterat ännu
        • Baker Heart and Diabetes Institute
        • Kontakt:
    • Alabama
      • Birmingham, Alabama, Förenta staterna, 35235
        • Upphängd
        • Cahaba Research, Inc. - Trussville Location
    • Arizona
      • Gilbert, Arizona, Förenta staterna, 85296
        • Har inte rekryterat ännu
        • Mission Research Institute - Gilbert
        • Kontakt:
      • Paradise Valley, Arizona, Förenta staterna, 85253
        • Upphängd
        • Helios Clinical Research - Paradise Valley
      • Phoenix, Arizona, Förenta staterna, 85028
        • Upphängd
        • Helios Clinical Research - Phoenix
    • Arkansas
      • Little Rock, Arkansas, Förenta staterna, 72211
        • Upphängd
        • Woodland International Research Group, Inc.
    • California
      • Canoga Park, California, Förenta staterna, 91304
      • Concord, California, Förenta staterna, 94520
        • Upphängd
        • John Muir Physician Network Clinical Research Center
      • Escondido, California, Förenta staterna, 92025
        • Upphängd
        • Neighborhood Healthcare - Escondido
      • Lincoln, California, Förenta staterna, 95648
        • Upphängd
        • Clinical Trials Research - Lincoln
      • Long Beach, California, Förenta staterna, 90815
        • Upphängd
        • ARK Clinical Research
      • Northridge, California, Förenta staterna, 91325
        • Upphängd
        • Valley Clinical Trials, Inc.
      • Spring Valley, California, Förenta staterna, 91978
        • Upphängd
        • Encompass Clinical Research, Spring Valley
      • Walnut Creek, California, Förenta staterna, 94598
        • Upphängd
        • Diablo Clinical Research
      • West Hills, California, Förenta staterna, 91307
        • Upphängd
        • Focus Clinical Research
    • Florida
      • Clearwater, Florida, Förenta staterna, 33765
        • Upphängd
        • Clinical Research of West Florida, Inc.
      • Fort Myers, Florida, Förenta staterna, 33912
        • Upphängd
        • Covenant Metabolic Specialists, LLC - Fort Myers
      • Hollywood, Florida, Förenta staterna, 33024
        • Upphängd
        • Encore Medical Research
      • Lakeland, Florida, Förenta staterna, 33803
        • Upphängd
        • Accel Research Sites - Lakeland
      • Lakeland, Florida, Förenta staterna, 33805
        • Upphängd
        • Clinical Research of Central Florida - Lakeland
      • Largo, Florida, Förenta staterna, 33777
        • Upphängd
        • Tampa Bay Medical Research - Largo
      • Miami, Florida, Förenta staterna, 33165
        • Upphängd
        • New Horizon Research Center-Miami-69732
      • Riverview, Florida, Förenta staterna, 33578
        • Upphängd
        • Covenant Metabolic Specialists, LLC - Brandon
      • University Park, Florida, Förenta staterna, 34201
        • Upphängd
        • Covenant Metabolic Specialists, LLC - Sarasota
      • Weston, Florida, Förenta staterna, 33331
        • Upphängd
        • Encore Medical Research - Weston
      • Winter Park, Florida, Förenta staterna, 32789
        • Upphängd
        • Conquest Research
    • Georgia
      • Columbus, Georgia, Förenta staterna, 31904
        • Upphängd
        • Centricity Research, Endocrine Consultants
      • Fayetteville, Georgia, Förenta staterna, 30214
        • Upphängd
        • Javara-Fayetteville-67354
      • Lawrenceville, Georgia, Förenta staterna, 30046
        • Har inte rekryterat ännu
        • Balanced Life Health Care Solutions
        • Kontakt:
      • Union City, Georgia, Förenta staterna, 30291
        • Har inte rekryterat ännu
        • Rophe Adult and Pediatric Medicine
        • Kontakt:
    • Hawaii
      • Honolulu, Hawaii, Förenta staterna, 96817
        • Har inte rekryterat ännu
        • Pacific Diabetes & Endocrine Center
        • Kontakt:
    • Idaho
      • Blackfoot, Idaho, Förenta staterna, 83221
        • Upphängd
        • Elite Clinical Trials - Blackfoot
      • Idaho Falls, Idaho, Förenta staterna, 83404
        • Har inte rekryterat ännu
        • Family First Clinical Research
        • Kontakt:
      • Meridian, Idaho, Förenta staterna, 83646
    • Kentucky
      • Lexington, Kentucky, Förenta staterna, 40509
        • Upphängd
        • AMR Lexington
    • Maryland
      • Rockville, Maryland, Förenta staterna, 20852
        • Har inte rekryterat ännu
        • Endocrine and Metabolic Consultants
        • Kontakt:
    • Michigan
      • Buckley, Michigan, Förenta staterna, 49620
        • Har inte rekryterat ännu
        • Northern Pines Health Center - Buckley
        • Kontakt:
      • Dearborn, Michigan, Förenta staterna, 48126
        • Upphängd
        • Revival Research Institute, LLC - Dearborn
      • Troy, Michigan, Förenta staterna, 48098
        • Upphängd
        • Arcturus Healthcare - Troy Internal Medicine Research Division
    • Minnesota
      • Minneapolis, Minnesota, Förenta staterna, 55416
        • Har inte rekryterat ännu
        • International Diabetes Center
        • Kontakt:
    • Mississippi
      • Olive Branch, Mississippi, Förenta staterna, 38654
        • Upphängd
        • Olive Branch Family Medical Center
    • Montana
      • Kalispell, Montana, Förenta staterna, 59901
        • Har inte rekryterat ännu
        • Logan Health Research - Kalispell
        • Kontakt:
      • Missoula, Montana, Förenta staterna, 59804
    • Nevada
      • Las Vegas, Nevada, Förenta staterna, 89128
    • New Mexico
      • Albuquerque, New Mexico, Förenta staterna, 87102
    • New York
      • Brooklyn, New York, Förenta staterna, 11215
        • Upphängd
        • Ellipsis Research Group - Brooklyn
    • North Carolina
      • Fayetteville, North Carolina, Förenta staterna, 28304
        • Upphängd
        • Javara Inc. - Cape Fear Valley Medical Center
      • Greensboro, North Carolina, Förenta staterna, 27408
        • Upphängd
        • PharmQuest Life Sciences
      • Morehead City, North Carolina, Förenta staterna, 28557
        • Upphängd
        • Centricity Research - Morehead City
    • Ohio
      • Canton, Ohio, Förenta staterna, 44718
        • Upphängd
        • Diabetes & Endocrinology Associates of Stark County
      • Maumee, Ohio, Förenta staterna, 43537
        • Upphängd
        • Advanced Medical Research - Maumee
    • Oklahoma
      • Oklahoma City, Oklahoma, Förenta staterna, 73134
        • Upphängd
        • Tekton Research Oklahoma City
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Förenta staterna, 15236
        • Upphängd
        • Preferred Primary Care Physicians-Pittsburgh-63932
      • Uniontown, Pennsylvania, Förenta staterna, 15401
        • Upphängd
        • Preferred Primary Care Physicians - Matthew Drive
    • South Carolina
      • Bluffton, South Carolina, Förenta staterna, 29910
        • Har inte rekryterat ännu
        • PanAmerican Clinical Research - Bluffton
        • Kontakt:
      • Spartanburg, South Carolina, Förenta staterna, 29303
        • Avslutad
        • Spartanburg Medical Research
    • Tennessee
      • Chattanooga, Tennessee, Förenta staterna, 37411
        • Upphängd
        • University Diabetes & Endocrine Consultants
      • Memphis, Tennessee, Förenta staterna, 38115
    • Texas
      • Austin, Texas, Förenta staterna, 78731
        • Upphängd
        • Texas Diabetes and Endocrinology - Central Austin
      • Brownsville, Texas, Förenta staterna, 78520
        • Upphängd
        • South Texas Research Institute - Brownsville
      • Conroe, Texas, Förenta staterna, 77384
        • Upphängd
        • Privia Medical Group Gulf Coast, PLLC
      • Dallas, Texas, Förenta staterna, 75390-8837
        • Har inte rekryterat ännu
        • University of Texas Southwestern Medical Center
        • Kontakt:
      • Georgetown, Texas, Förenta staterna, 78626
        • Upphängd
        • Pinnacle Clinical Research - Georgetown
      • Houston, Texas, Förenta staterna, 77089
      • Houston, Texas, Förenta staterna, 77084
        • Upphängd
        • Biopharma Informatic, Inc. Research Center
      • Mesquite, Texas, Förenta staterna, 75149
        • Har inte rekryterat ännu
        • Southern Endocrinology Associates
        • Kontakt:
      • San Antonio, Texas, Förenta staterna, 78222
        • Upphängd
        • Pinnacle Clinical Research - San Antonio
      • San Antonio, Texas, Förenta staterna, 78229
        • Upphängd
        • Pinnacle Clinical Research, LLC
      • Shavano Park, Texas, Förenta staterna, 78231
    • Utah
      • Salt Lake City, Utah, Förenta staterna, 84117
        • Upphängd
        • Olympus Family Medicine
    • Virginia
      • Newport News, Virginia, Förenta staterna, 23606
        • Har inte rekryterat ännu
        • Tidewater Physicians Multispecialty Group
        • Kontakt:
    • Washington
      • Redmond, Washington, Förenta staterna, 98052
        • Upphängd
        • ERA Health Research - Redmond
      • Ahmedabad, Indien, 380006
        • Har inte rekryterat ännu
        • Gujarat Endocrine Centre
        • Kontakt:
      • Ahmedabad, Indien, 380006
        • Har inte rekryterat ännu
        • Sardar Vallabhbhai Patel Institute of Medical Sciences and Research
        • Kontakt:
      • Bhubaneswar, Indien, 751019
        • Har inte rekryterat ännu
        • AIIMS Bhubaneshwar
        • Kontakt:
      • Cuttack, Indien, 753007
        • Har inte rekryterat ännu
        • S.C.B. Medical College & Hospital
        • Kontakt:
      • Hyderabad, Afzalgunj, Indien, 500012
        • Har inte rekryterat ännu
        • Osmania Medical College & Hospital
        • Kontakt:
      • Kolhāpur, Indien, 416003
        • Har inte rekryterat ännu
        • Shree Mahalaxmi Diatone Institute
        • Kontakt:
      • Lucknow, Indien, 226 014
        • Har inte rekryterat ännu
        • Sanjay Gandhi Post Graduate Institute of Medical Sciences
        • Kontakt:
      • Nagpur, Indien, 440010
        • Har inte rekryterat ännu
        • Diabetes Care and Research Centre
        • Kontakt:
      • Nashik, Indien, 422002
        • Har inte rekryterat ännu
        • Supe Heart & Diabetes Hospital & Research Centre
        • Kontakt:
      • New Delhi, Indien, 110029
        • Har inte rekryterat ännu
        • AIIMS, New Delhi
        • Kontakt:
      • Pune, Indien, 411004
        • Har inte rekryterat ännu
        • Deenanath Mangeshkar Hospital and Research Centre
        • Kontakt:
      • Trivandrum, Indien, 695032
        • Har inte rekryterat ännu
        • Jothydev's Diabetes Research Centre
        • Kontakt:
      • Visakhapatnam, Indien, 530040
        • Har inte rekryterat ännu
        • Vishakha Institute of Medical Sciences
        • Kontakt:
      • Québec, Kanada, G1G 5X1
        • Rekrytering
        • Recherche Clinique Sigma Inc.
        • Kontakt:
    • British Columbia
      • New Westminster, British Columbia, Kanada, V3L 3W4
        • Rekrytering
        • Fraser Clinical Trials
        • Kontakt:
    • Ontario
      • Brampton, Ontario, Kanada, L6S 0C6
        • Rekrytering
        • Centricity Research (Brampton)
        • Kontakt:
      • Concord, Ontario, Kanada, L4K 4M2
        • Rekrytering
        • Centricity Research (Vaughan)
        • Kontakt:
      • Nepean, Ontario, Kanada, K2J 0V2
        • Rekrytering
        • Centricity Research (Nepean)
        • Kontakt:
      • Toronto, Ontario, Kanada, M6G 1M2
        • Rekrytering
        • Diabetes Heart Research Centre
        • Kontakt:
      • Toronto, Ontario, Kanada, M4G 3E8
        • Rekrytering
        • Centricity Research (Bayview)
        • Kontakt:
      • Toronto, Ontario, Kanada, M9V 4B4
        • Rekrytering
        • Albion Finch Medical Centre
        • Kontakt:
    • Quebec
      • Montreal, Quebec, Kanada, H4A 3T2
        • Rekrytering
        • Applied Medical Informatics Research Inc.
        • Kontakt:
      • Montreal, Quebec, Kanada, H4J 1E3
        • Rekrytering
        • Endocrinologie Oasis Inc
        • Kontakt:
      • Auckland, Nya Zeeland, 0626
      • Hamilton, Nya Zeeland, 3204
    • Dunedin
      • Central Dunedin, Dunedin, Nya Zeeland, 9016

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion criteria:

  1. Male or female, age ≥18 years at the time of signing informed consent, and at least the legal age of consent in countries where it is >18 years

  2. Diagnosed with type 2 diabetes mellitus (T2D) (e.g. American diabetes association (ADA)/European association for the study of diabetes (EASD) guidelines) and must meet requirements for one of background therapy parts A, B or C:

    1. Part A: Naïve to insulin therapy and have not used oral or injectable anti-hyperglycaemic (diabetes) medication for at least 90 days prior to screening (Visit 1) and glycosylated haemoglobin A1c (HbA1c) ≥7.0 (≥53 mmol/mol) and <9.5% (<80 mmol/mol) as measured by the central laboratory at screening (Visit 1);
    2. Part B: Treated with stable dose of oral antidiabetic medication (OAD) for 90 days prior to screening (Visit 1) as monotherapy or combination of: Maximum tolerated dose of metformin and/or Maximum tolerated dose of sulfonylurea and/or Maximum tolerated dose of sodium-glucose cotransporter 2 inhibitor (SGLT2i) and HbA1c ≥7.0% (≥53 mmol/mol) and <10.5% (<91 mmol/mol) as measured by the central laboratory at screening (Visit 1);
    3. Part C: Stable use of basal insulin at a dose of ≥20 international units (IU)/day with or without stable dose of metformin and/or SGLT2i for 90 days prior to screening (Visit 1) and HbA1c ≥7.0% (≥53 mmol/mol) and <10.5% (<91 mmol/mol) as measured by the central laboratory at screening (Visit 1)
  3. Body mass index (BMI) ≥23 kg/m2 at screening (Visit 1)

  4. Signed and dated written informed consent in accordance with international council for harmonisation - good clinical practice (ICH-GCP) and local legislation prior to admission to the trial

  5. Woman (or women) of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per international council for harmonisation of technical requirements for pharmaceuticals for human use M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly.

  6. In the investigator's opinion, participants are well-motivated, capable, and willing to: Learn how to self-inject the investigational medicinal product (IMP), as required for this protocol (persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject the IMP); Inject the IMP or accept injection from a designated person; Follow study procedures for the duration of the study, including, but not limited to: follow lifestyle advice (for example, dietary restrictions and exercise plan), maintain a diary, complete required questionnaires, and handle the IMP as described in the instructions for use (IFU)

Exclusion criteria:

  1. Type 1 diabetes mellitus (T1D) or latent autoimmune diabetes in adults (LADA)
  2. Treatment within 90 days before screening (Visit 1) up to and including randomisation (Visit 2) with any: glucagon-like peptide-1 receptor (GLP-1R) agonists including GLP-1R agonist/glucose-dependent insulinotropic polypeptide (GIP) combinations, amylin or incretin combinations; Glucose-lowering drugs other than stated in the inclusion criteria for each part (i.e. metformin, Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i), basal insulin, depending on the background therapy part); Glucose-lowering investigational drug; Any anti-obesity medication including bupropion/naltrexone, orlistat, phentermine, and phentermine/topiramate
  3. History of ketoacidosis or hyperosmolar state or coma within the last 6 months before screening (Visit 1) up to and including randomisation (Visit 2)
  4. Hypoglycaemia unawareness or a history of severe hypoglycaemia within the last 3 months before screening (Visit 1) up to and including randomisation (Visit 2)
  5. Diabetic retinopathy or maculopathy currently under treatment, or that is reasonably anticipated to require such treatment over the duration of the study
  6. Body weight change (self-reported) >5% within 90 days before screening (Visit 1)
  7. Previous or planned (during the trial period) treatment for obesity with surgery or a weight loss device, including any prior bariatric surgery. The following are allowed: (1) liposuction and/or abdominoplasty, if performed >1 year before screening (Visit 1), (2) lap banding, if the band has been removed >1 year before screening (Visit 1), (3) intragastric balloon, if the balloon has been removed >1 year before screening (Visit 1), (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed >1 year before screening (Visit 1).
  8. Answered "yes" to any of the suicide-related behaviours (Actual attempt, Interrupted attempt, Aborted attempt, Preparatory act or behaviour) or to the non-suicidal self-injurious behaviour question on the "Suicidal Behaviour" section of the Columbia-Suicide Severity Rating Scale (C-SSRS) related to the past 2 years before screening (Visit 1) up to and including randomisation (Visit 2)
  9. Further exclusion criteria apply.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Placebo-jämförare: Part A: Placebo

Placebo as an add-on to diet and exercise.

Placebo

Experimentell: Part A: Low-dose survodutide

Low-dose survodutide as an add-on to diet and exercise.

Survodutide

Andra namn:
  • BI 456906
Experimentell: Part A: High-dose survodutide

High-dose survodutide as add-on to diet and exercise

Survodutide

Andra namn:
  • BI 456906
Placebo-jämförare: Part B: Placebo

Placebo as an add-on to anti-diabetic drugs.

Placebo

Experimentell: Part B: Low-dose survodutide

Low-dose survodutide as an add-on to anti-diabetic drugs.

Survodutide

Andra namn:
  • BI 456906
Experimentell: Part B: High-dose survodutide

High-dose survodutide as an add-on to anti-diabetic drugs.

Survodutide

Andra namn:
  • BI 456906
Placebo-jämförare: Part C: Placebo

Placebo as an add-on to basal insulin therapy with or without anti-diabetic drugs.

Placebo

Experimentell: Part C: Low-dose survodutide

Low-dose as an add-on to basal insulin therapy with or without anti-diabetic drugs.

Survodutide

Andra namn:
  • BI 456906
Experimentell: Part C: High-dose survodutide

High-dose as an add-on to basal insulin therapy with or without anti-diabetic drugs.

Survodutide

Andra namn:
  • BI 456906

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Absolute change in glycosylated haemoglobin A1c (HbA1c) (%) from baseline to Week 41
Tidsram: At baseline and Week 41.
At baseline and Week 41.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Key secondary endpoint: Absolute change in HbA1c (%) from baseline to Week 53
Tidsram: At baseline and Week 53.
At baseline and Week 53.
Key secondary endpoint: Achievement of HbA1c <6.5% (yes/no) at Week 41
Tidsram: At baseline and Week 41.
At baseline and Week 41.
Achievement of HbA1c <5.7% (yes/no) at Week 41
Tidsram: At Week 41.
At Week 41.
Absolute change in fasting plasma glucose (mg/dL) from baseline to Week 53
Tidsram: At baseline and Week 53.
At baseline and Week 53.
Percent change in body weight (kg) from baseline to Week 53
Tidsram: At baseline and Week 53.
At baseline and Week 53.
Relative change in non-HDL (high-density lipoprotein) cholesterol from baseline to Week 53
Tidsram: At baseline and Week 53.
At baseline and Week 53.
Relative change in triglycerides from baseline to Week 53
Tidsram: At baseline and Week 53.
At baseline and Week 53.
Relative change in urinary albumin-to-creatinine ratio (UACR) from baseline to Week 53 as a continuous variable
Tidsram: At baseline and Week 53.
At baseline and Week 53.
Absolute change in systolic blood pressure (SBP, mmHg) from baseline to Week 53
Tidsram: At baseline and Week 53.
At baseline and Week 53.
Part C: Absolute change in daily basal insulin dose from baseline to Week 53
Tidsram: At baseline and Week 53.
At baseline and Week 53.
Estimated glomerular filtration rate (CKD-EPIcr) slope of change from baseline to Week 53
Tidsram: At baseline and Week 53.

CKD-EPIcr: Chronic Kidney Disease Epidemiology Collaboration creatinine equation

At baseline and Week 53.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Användbara länkar

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

24 augusti 2026

Primärt slutförande (Beräknad)

17 januari 2028

Avslutad studie (Beräknad)

1 maj 2028

Studieregistreringsdatum

Först inskickad

5 augusti 2026

Först inskickad som uppfyllde QC-kriterierna

5 augusti 2026

Första postat (Faktisk)

10 augusti 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

29 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

28 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

Tidsram för IPD-delning

One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Kriterier för IPD Sharing Access

For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera